The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected… The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected…

MLB Sees Dramatic Drop In PED Suspensions

2025/12/03 21:41

Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions.

getty

Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing.

If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16.

The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances.

Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D.

For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,300.

Of those tests, two resulted in adverse findings that led to suspensions. In all cases, players are retested if there are adverse findings. Should the findings remain and fall under the substances that result in suspension, a player can appeal the suspension. Therefore, when a suspension is announced, it is a considerable period of time after the player tests positive for PEDs.

For 2025, there were two players suspended for violating the drug program:

On May 18th, José Alvarado received an 80-game suspension without pay after testing positive for exogenous Testosterone. On May 31st, Jurickson Profar received an 80-game suspension without pay after testing positive for Chorionic Gonadotrophin (hCG). In both cases, the suspensions were for performance-enhancing substances.

Therapeutic Use Exemptions For Otherwise Banned Substances

The league and MLBPA have allowed a system in which players, through a doctor’s care, and apply for what is called a Therapeutic Use Exemption, or TUEs. The TUEs is granted after comprehensive medical documentation to prove the medical need for the medication and demonstrate that the treatment only returns the athlete to a normal level of health, rather than providing an unfair advantage. In the vast majority of the TUEs granted each year, the exemption is made for Attention Deficit Hyperactivity Disorder (ADHD) medications. These medications are often amphetamine derivatives, and given that amphetamines are banned in MLB, the player would need an exemption to use such meds to address ADHD.

In years past, the number of ADHD TUEs has reached over 100, which raised the question as to whether there was a fundamental loophole in the drug testing program.

But over the years, these numbers have declined dramatically. For 2025, there was a total of 57 TUEs granted, with 54 for ADHD, along with one each granted for hypertension, sleep disorder, and hormone function. In all cases, the players granted TUEs are not released in the annual report. The drug testing program does not allow for therapeutic use exemptions for human growth hormone.

The 57 total therapeutic use exemptions in 2025 is a -37% drop from the 91 granted in 2020, and shows the drop over just the past six years. While there will likely never be a day when there are no suspensions and no therapeutic use exemptions, for now, at least within the drug program, Major League Baseball is about as free from PEDs as it may ever be.

The table below shows the number of PED suspensions, the total number of therapeutic use exemptions, and the number of those that are ADHD related from 2020 to 2025.

Graphical representation of MLB drug suspension, TUEs, and those that are for ADHD

Maury Brown

Source: https://www.forbes.com/sites/maurybrown/2025/12/03/mlb-sees-dramatic-drop-in-ped-suspensions/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

US Dollar Index (DXY) hovers near multi-week low ahead of US PCE data

US Dollar Index (DXY) hovers near multi-week low ahead of US PCE data

The post US Dollar Index (DXY) hovers near multi-week low ahead of US PCE data appeared on BitcoinEthereumNews.com. The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, struggles to capitalize on the overnight bounce from its lowest level since late October and trades with a mild negative bias during the Asian session on Friday. The index is currently placed around the 99.00 mark, down less than 0.10% for the day, as traders now await the crucial US inflation data before placing fresh directional bets. The September US Personal Consumption Expenditure (PCE) Price Index will be published later today and will be scrutinized for more cues about the Federal Reserve’s (Fed) future rate-cut path. This, in turn, will play a key role in determining the next leg of a directional move for the Greenback. In the meantime, dovish US Federal Reserve (Fed) expectations overshadow Thursday’s upbeat US labor market reports and continue to act as a headwind for the buck. Recent comments from several Fed officials suggested that another interest rate cut in December is all but certain. The CME Group’s FedWatch Tool indicates an over 85% probability of a move next week. Furthermore, reports suggest that White House National Economic Council Director Kevin Hassett is seen as the frontrunner to become the next Fed Chair and is expected to enact US President Donald Trump’s calls for lower rates, which, in turn, favors the USD bears. Nevertheless, the DXY remains on track to register losses for the second straight week, and the fundamental backdrop suggests that the path of least resistance for the index remains to the downside. Hence, any attempted recovery is more likely to get sold into and remain limited. US Dollar Price Last 7 Days The table below shows the percentage change of US Dollar (USD) against listed major currencies last 7 days. US Dollar was the strongest against the Swiss…
Share
BitcoinEthereumNews2025/12/05 13:43
SSP Stock Surges 11% On FY25 Earnings And European Rail Review

SSP Stock Surges 11% On FY25 Earnings And European Rail Review

The post SSP Stock Surges 11% On FY25 Earnings And European Rail Review appeared on BitcoinEthereumNews.com. SSP Group stock rebounded strongly today. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Shares in travel food retailer SSP Group rose sharply today after the company posted solid FY25 results, highlighting good growth in two of its four regional divisions, and a decision to review its under‑performing Continental European rail business. The food and beverage (F&B) company’s stock closed 11.3% up in London on the back of a revenue rise of 7.8% (at constant currency) to £3.6 billion ($4.8 billion) in the 12 months to September. Operating profit jumped by 12.7% to £223 million ($298 million). Under statutory IFRS reporting, however, operating profit fell 58% to £86 million, which SSP said in a statement “reflected £183 million of non‑underlying expenses and impairment charges.” The decision to review its rail business in Continental Europe—the biggest of the F&B giant’s four divisions by revenue at £1,205 million ($1,607 million)—was welcomed by the market, given its weak performance of 2% like-for-like (LFL) growth. A carrot was also dangled— a reward to shareholders arising from the July IPO of SSP’s Indian joint venture Travel Food Services (TFS) with K Hospitality, India’s largest privately held F&B company. SSP Group CEO Patrick Coveney said in a statement: “We acknowledge there is more to do to strengthen our operational performance, most notably in Continental Europe, where we have now reset our team, model, and balance sheet, and have a range of initiatives underway. In addition, we are launching a wide-ranging review of our rail business in Continental Europe. We are also considering options to realise value for our shareholders in line with the delivery of the TFS free float requirement.” SSP currently retains a 50.01% stake in TFS and said: “We believe that India’s market potential, combined with TFS’s attractive…
Share
BitcoinEthereumNews2025/12/05 13:37
GOAT Foundation unveils tokenomics for $GOATED token launch

GOAT Foundation unveils tokenomics for $GOATED token launch

The post GOAT Foundation unveils tokenomics for $GOATED token launch appeared on BitcoinEthereumNews.com. The GOAT Foundation recently announced the details for its token generation event for $GOATED. The token is meant to support the network by serving as a reward mechanism and a governance token. Summary $GOATED will serve as both a governance tool and a reward mechanism within the Bitcoin ZKRollup GOAT Network Nearly 40% of the 1 billion $GOATED supply will go to the ecosystem’s mining rewards pool, while the remaining tokens will be allocated across team members, early supporters, the on-chain treasury, and community incentives such as airdrops. The Bitcoin ZKRollup GOAT Network has recently launched its own foundation to support the network in aiming to advance the Bitcoin ecosystem by scaling BTC performance and providing BTC yield while maintaining native BTC security. The independent entity has been dubbed the GOAT Foundation. Alongside the launch of GOAT Foundation, the network has revealed more details regarding the upcoming token generation event for its native token launch. Although the GOAT Foundation has yet to reveal an official release date, signs point to a release in the later half of 2025. According to the official announcement, the $GOATED token will be used to unlock key utilities across the GOAT network ecosystem. The token will be used for staking or locking to enhance BTC (BTC) yield rates, providing mining rewards and incentivizing developers among other use cases. In addition, $GOATED holders will be able to propose and vote on decisions regarding the GOAT Network. Stakers of $GOATED will also be able to increase their chances of being chosen to become sequencers, which directly earn them BTC transaction fees. This initiative is meant to incentivize users and node operators to engage with the $GOATED token. GOAT Foundation’s tokenomics for $GOATED The largest portion of $GOATED will be allocated to the GOAT ecosystem mining pool. Nearly…
Share
BitcoinEthereumNews2025/09/24 17:14